**Aims and objectives of this session**
The three lectures of ESU course 48 will provide comprehensive state-of-the-art information about currently available therapies for hormone-naïve and castration resistant prostate cancer, such as various forms of primary androgen deprivation, immunotherapy, chemotherapy, and therapies approved for CRPC. After the course, attendees should be able to adequately treat patients with metastatic prostate cancer at all disease stages.

**Treatment of kastration-sensitive metastatic prostate cancer**
K. Miller, Berlin (DE)

**What is the role of chemotherapy and immunotherapy in patients with CRPC?**
G. Mickisch, Bremen (DE)

**Treatment of mCRPC – sequence or combination?**
K. Pummer, Graz (AT)

**Case discussion**
G. Mickisch, Bremen (DE)
K. Miller, Berlin (DE)
K. Pummer, Graz (AT)